M&A Deal Summary

Celldex Therapeutics Acquires Alteris Therapeutics

On October 12, 2005, Celldex Therapeutics acquired life science company Alteris Therapeutics

Acquisition Highlights
  • This is Celldex Therapeutics’ 1st transaction in the Life Science sector.
  • This is Celldex Therapeutics’ 1st transaction in the United States.
  • This is Celldex Therapeutics’ 1st transaction in Pennsylvania.

M&A Deal Summary
Date 2005-10-12
Target Alteris Therapeutics
Sector Life Science
Buyer(s) Celldex Therapeutics
Deal Type Add-on Acquisition

Target

Alteris Therapeutics

Philadelphia, Pennsylvania, United States
Alteris Therapeutics, Inc. engages in the discovery and development of therapeutics and vaccines based on alternative gene splice forms for the treatment of cancer. I

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Celldex Therapeutics

Hampton, New Jersey, United States
Category Company
Founded 1983
Sector Life Science
Employees148
Revenue 7M USD (2023)
DESCRIPTION

Celldex Therapeutics is an integrated bio pharmaceutical company that applies its comprehensive precision targeted immunotherapy platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex Therapeutics was founded in 1983 and is based in Hampton, New Jersey.

DEAL STATS #
Overall 1 of 3
Sector (Life Science) 1 of 3
Type (Add-on Acquisition) 1 of 3
State (Pennsylvania) 1 of 1
Country (United States) 1 of 3
Year (2005) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2009-03-29 CuraGen

Branford, Connecticut, United States

CuraGen has a portfolio of 11 fully-owned, human antibodies that the Company selected, optimized and advanced during its collaboration with Abgenix (acquired by Amgen). CR011, currently in Phase 2 studies, is an antibody-drug conjugate that targets GPNMB, a protein that is highly expressed in metastatic breast cancer and melanoma. CR011 has shown promising early evidence of anti-tumor activity, including objective tumor responses, in patients with breast cancer and unresectable stage III and IV melanoma.

Buy $95M
Mergr

Product

Company

Legal